GlassScriptPhysician profile
Peter A Le Witt
NPI 1750434114
$373,165.54
in general payments reported to CMS, 2019-2025
29 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128K · 2020: $65K · 2021: $91K · 2022: $19K · 2023: $21K · 2024: $2,211 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Honoraria: $22K · Travel and Lodging: $13K · Food and Beverage: $3,817 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,270.00 |
| Honoraria | $22,245.00 |
| Travel and Lodging | $13,492.15 |
| Food and Beverage | $3,816.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $124,360.74 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Acorda Therapeutics, INC | $69,089.12 | 2019-2021 | |
| Kyowa Kirin, INC. | $69,072.03 | 2019-2025 | Nourianz |
| Amneal Pharmaceuticals LLC | $35,635.03 | 2019-2025 | Crexont |
| Neurocrine Biosciences, INC. | $16,849.86 | 2019-2024 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $13,960.90 | 2019 | |
| Jazz Pharmaceuticals INC. | $9,699.80 | 2021-2025 | |
| Biogen, INC. | $8,045.79 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $7,369.67 | 2023-2025 | Nuplazid, Acp-711, Daybue |
| H. Lundbeck A S | $5,556.97 | 2025 | |
| Genentech, INC. | $4,095.00 | 2022-2024 | |
| Lundbeck LLC | $2,000.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,616.93 | 2025 | |
| Supernus Pharmaceuticals, INC. | $1,500.00 | 2021 | |
| Sage Therapeutics, LLC | $1,170.00 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $622.50 | 2020 | |
| Tolmar, INC. | $500.00 | 2023 | |
| Abbvie INC. | $480.36 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $426.67 | 2021 | |
| Dr.Reddy'S Laboratories,INC. | $347.00 | 2019 | |
| Boston Scientific Corporation | $200.65 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $149.01 | 2019-2024 | Dysport |
| Merz North America, INC. | $148.03 | 2019 | |
| Ge Healthcare | $108.82 | 2023 | |
| Alnylam Pharmaceuticals INC. | $107.10 | 2023 | Amvuttra |
| Ucb, INC. | $30.69 | 2025 | Fintepla |
| Csl Behring | $22.87 | 2025 | Hizentra |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Le Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.